Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301

European Journal of Cancer

Volumn 47, Issue 13, 2011, Pages 2052-2059

  Thomas, Huw D ^a   Wang, Lan Zhen ^a   Roche, Celine ^a,b   Bentley, Johanne ^a,c   Cheng, Yuzhu ^a,b   Hardcastle, Ian R ^a,b   Golding, Bernard T ^b   Griffin, Roger J ^a,b   Curtin, Nicola J ^a   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

CDK2; Cell cycle; Growth inhibition; Pharmacodynamics; Pharmacokinetics

Indexed keywords

6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; CYCLIN DEPENDENT KINASE 2; N ACETYL 4 (6 CYCLOHEXYLMETHOXY 9H PURIN 2 YLAMINO)BENZENESULPHONAMIDE POTASSIUM; NU 6301; NUCLEOPHOSMIN; PRODRUG; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PRODRUGS; PROTEIN KINASE INHIBITORS; PURINES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051863854     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.008     Document Type: Article

References (28)

1. S. Lapenna, and A. Giordano Cell cycle kinases as therapeutics for cancer Nat Rev Drug Discov 8 2009 547 566
2. G.I. Shapiro Cyclin-dependent kinase pathways as targets for cancer treatment J Clin Oncol 24 2006 1770 1783 (Pubitemid 46628473)
3. M. Malumbres, P. Pearello, M. Barbacid, and J.R. Bischoff CDK inhibitors in cancer therapy: what is next? Trends in Pharm Sci 29 2007 16 21
4. A. Van der Heuvel, and E. Harlow Distinct roles for cyclin-dependent kinases in cell cycle control Science 262 1993 2050 2054 (Pubitemid 24041887)
5. B. Hu, J. Mitra, S. van der Heuvel, and G.H. Enders S and G2 phase roles for CDK2 revealed by inducible expression of a dominant-negative mutant in human cells Mol Cell Biol 21 2001 2755 2765
6. O. Tetsu, and F. McCormick Proliferation of cancer cells despite CDK2 inhibition Cancer cell 3 2003 233 245 (Pubitemid 37443879)
7. S. Ortega, I. Presto, and J. Odajima Cyclin-dependent kinase 2 is essential for meiotic but not for mitotic cell division in mice Nat Genet 35 2003 25 31 (Pubitemid 37048592)
8. C. Berthet, E. Aleem, V. Coppola, L. Tessarollo, and P. Kaldis CDK2 knockout mice are viable Curr Biol 13 2002 1175 1185
9. M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer 9 2009 153 166
10. H. Hochhegger, S. Takeda, and T. Hunt Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Net Rev Mol Cell Biol 9 2008 910 916
11. S. Campaner, M. Doni, and P. Hydbring CDK2 suppresses cellular senescence induced by the c-myc oncogene Nat Cell Biol 12 2010 54 60
12. A. Goga, D. Yang, A.D. Tward, D.O. Morgan, and J.M. Bishop Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC Nat Med 13 2007 820 827 (Pubitemid 47038193)
13. J.J. Molenaar, M.E. Ebus, and D. Geerts Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells PNAS 106 2009 12968 12973
14. E. Macias, Y. Kim, P.L. Miliania de Marval, A. Klein-Szanto, and L. Rodriguez-Puebla CDK2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis Cancer Res 67 2007 9713 9720 (Pubitemid 47621218)
15. P. Hydbring, F. Bahram, and Y. Su Phosphorylation by CDK2 is required for myc to repress ras-induced senescence in cotransformation PNAS 107 2010 58 63
16. L. Bagella, A. Sun, and T. Tonini A small molecule based on the pRb/p130 spacer domain leads to inhibition of CDK2 activity, cell cycle arrest and tumor growth reduction in vivo Oncogene 26 2007 1829 1839 (Pubitemid 46474634)
17. A.C. Faber, and T.C. Chiles Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas Cell Cycle 6 2007 2982 2989
18. J. Du, H.R. Widlund, and M.A. Horstmann Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF Cancer Cell 6 2004 565 576 (Pubitemid 40017700)
19. A.J. Deans, K.K. Khanna, and C.J. McNees Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA-1 deficient cancer Cancer Res 66 2006 8219 8226 (Pubitemid 44299190)
20. H. Huang, K.M. Regan, Z. Lou, J. Chen, and D.J. Tindall CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage Science 314 2006 294 297 (Pubitemid 44571973)
21. T.G. Davies, J. Bentley, and C.E. Arris Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor Nat Struc Biol 9 2002 745 749
22. N. Johnson, J. Bentley, and L.-Z. Wang Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cell lines Brit J Cancer 102 2010 342 350
23. L. Krasinska, E. Besnard, and E. Cot Cdk1 and Cdk2 activity levels determine the efficient of replication origin firing in Xenopus EMBO J 27 2008 758 769 (Pubitemid 351506679)
24. B.A. Christian, M.R. Grever, J.C. Byrd, and T.S. Lin Flavopiridol in chronic lymphocytic leukemia: a concise review Clin Lymphoma Myeloma 9 Suppl 3 2009 S179 S185
25. J. Wesierska-Gadek, and G. Schmid Dual action of the inhibitors of cycling-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein Expert Opin Investig Drugs 15 2006 23 38 (Pubitemid 43034149)
26. S.K. Singh, S. Vobbalareddy, and S.R. Kalleda N-Acylated sulfonamide sodium salt: A prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5- phenyl-3-trifluoromethylpyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors Bioorg Med Chem Lett 16 2006 3921 3926 (Pubitemid 43903224)
27. P. Huang, P.J. Connolly, R. Lin, S. Emmanuel, and S. Middleton A Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621 Bioorg Med Chem Lett 16 2006 3641 3693
28. L. Krasinska, E. Cot, and D. Fisher Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle Cell cycle 7 2008 1702 1708 (Pubitemid 351988734)